Rhumbline Advisers Purchases 13,379 Shares of Amgen Inc. (NASDAQ:AMGN)

Rhumbline Advisers increased its position in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 1.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 945,681 shares of the medical research company’s stock after acquiring an additional 13,379 shares during the quarter. Rhumbline Advisers’ holdings in Amgen were worth $212,750,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in Amgen during the 4th quarter worth approximately $26,000. Norwood Financial Corp purchased a new stake in Amgen during the 4th quarter worth approximately $28,000. PYA Waltman Capital LLC purchased a new stake in Amgen during the 4th quarter worth approximately $34,000. Econ Financial Services Corp purchased a new stake in Amgen during the 4th quarter worth approximately $34,000. Finally, Level Financial Advisors Inc. purchased a new stake in Amgen during the 4th quarter worth approximately $39,000. Hedge funds and other institutional investors own 79.01% of the company’s stock.

Shares of NASDAQ AMGN traded down $1.32 during mid-day trading on Friday, reaching $243.40. The company’s stock had a trading volume of 2,631,841 shares, compared to its average volume of 3,190,039. The stock has a 50-day moving average of $241.68 and a two-hundred day moving average of $227.38. The stock has a market capitalization of $130.02 billion, a P/E ratio of 23.96, a P/E/G ratio of 1.67 and a beta of 0.58. The company has a debt-to-equity ratio of 39.31, a quick ratio of 1.09 and a current ratio of 1.44. Amgen Inc. has a 1-year low of $198.64 and a 1-year high of $258.45.

Amgen (NASDAQ:AMGNGet Rating) last issued its earnings results on Wednesday, April 27th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.22 by $0.03. The business had revenue of $6.24 billion during the quarter, compared to analysts’ expectations of $6.09 billion. Amgen had a net margin of 21.75% and a return on equity of 165.95%. During the same period in the prior year, the business earned $3.70 earnings per share. Analysts predict that Amgen Inc. will post 17.49 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Stockholders of record on Tuesday, May 17th will be given a $1.94 dividend. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.19%. The ex-dividend date is Monday, May 16th. Amgen’s dividend payout ratio (DPR) is 76.38%.

In related news, EVP Jonathan P. Graham sold 13,500 shares of the company’s stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total value of $3,264,435.00. Following the completion of the sale, the executive vice president now owns 37,333 shares of the company’s stock, valued at $9,027,492.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by corporate insiders.

Several analysts have recently commented on AMGN shares. BMO Capital Markets dropped their price objective on shares of Amgen from $263.00 to $243.00 in a report on Thursday, April 28th. Oppenheimer downgraded shares of Amgen to an “outperform” rating and set a $285.00 price objective on the stock. in a report on Tuesday, May 3rd. TheStreet downgraded shares of Amgen from a “b+” rating to a “c+” rating in a report on Wednesday, April 27th. Morgan Stanley dropped their price objective on shares of Amgen from $238.00 to $237.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 12th. Finally, Jefferies Financial Group upped their price objective on shares of Amgen from $266.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, February 9th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $240.40.

Amgen Profile (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Read More

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.